Novo Nordisk A/S Securities Lawsuit - Potential Recovery for Investors

Strategic Insights -

A class action securities lawsuit has been filed against Novo Nordisk A/S, seeking to recover losses of shareholders who were allegedly affected by securities fraud between May 7, 2025, and July 28, 2025. The lawsuit claims that the company provided false and misleading statements about its growth potential, understating the impact of the personalization exception to the compounded GLP-1 exclusion and overstating the likelihood of patients switching to Novo's branded alternatives.

Key Takeaways:

  • The lawsuit alleges that Novo Nordisk A/S provided false and misleading statements about its growth potential, which led to a decline in stock price from $69.00 to $53.94 per share on July 29, 2025, a decline of 21.83% in a single day.
  • The lawsuit claims that the company understated the impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood of patients switching to Novo's branded alternatives.
  • Novo announced a guide down on July 29, 2025, attributing the decreased growth expectations to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."
  • The lawsuit seeks to recover losses of shareholders who were adversely affected by the alleged securities fraud.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing the plaintiffs in the case.
  • The firm has secured hundreds of millions of dollars for aggrieved shareholders and has a track record of winning high-stakes cases.

Statistics:

  • The stock price of Novo Nordisk A/S declined by 21.83% in a single day from $69.00 to $53.94 per share on July 29, 2025.
  • The lawsuit alleges that the company provided false and misleading statements about its growth potential between May 7, 2025, and July 28, 2025.
  • The class action securities lawsuit is being represented by Levi & Korsinsky LLP, which has a team of over 70 employees and has extensive expertise in complex securities litigation.

Sources:

  • Newsfile Corp. - September 15, 2025
  • Levi & Korsinsky LLP - https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=167439&wire=5&utm_campaign=6
  • Levi & Korsinsky LLP - (212) 363-7500, jlevi@levikorsinsky.com